Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of MK-8353 combination therapies in advanced solid tumors
NL-OMON37039Phase 1Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mk-8353 in Nonhematologic neoplasms, colorectal cancer (CRC), melanoma and 1 more, sponsored by Merck & Co. Primary endpoints: Dose-limiting toxicities, Maximum tolerated dose and 3 more. Planned start Dec 2012; status: not yet recruiting.
02
Drugs
mk-8353
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON37039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37039.